The antiapoptotic gene survivin is highly expressed in human chondrosarcoma and promotes drug resistance in chondrosarcoma cells in vitro

BMC Cancer

Volumn 11, Issue , 2011, Pages

  Lechler, Philipp ^a   Renkawitz, Tobias ^a   Campean, Valentina ^b   Balakrishnan, Sanjeevi ^c   Tingart, Markus ^d   Grifka, Joachim ^a   Schaumburger, Jens ^a  

^a UNIVERSITY OF REGENSBURG   (Germany)

^b UNIVERSITY HOSPITAL ERLANGEN   (Germany)

^c IMPERIAL COLLEGE LONDON   (United Kingdom)

^d UNIVERSITY HOSPITAL RWTH AACHEN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

DOXORUBICIN; SURVIVIN; BIRC5 PROTEIN, HUMAN; INHIBITOR OF APOPTOSIS PROTEIN; SMALL INTERFERING RNA;

ADULT; AGED; APOPTOSIS; ARTICLE; CARTILAGE; CELL CYCLE ARREST; CELL CYCLE G2 PHASE; CELL CYCLE M PHASE; CHONDROSARCOMA; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; MALE; PROTEIN EXPRESSION; RNA INTERFERENCE; SURVIVIN GENE; TUMOR CELL; TUMOR GENE; BONE TUMOR; CANCER STAGING; CELL PROLIFERATION; DISEASE COURSE; DRUG EFFECT; DRUG RESISTANCE; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; PATHOLOGY; PATHOPHYSIOLOGY; TRANSGENE; TUMOR CELL LINE;

APOPTOSIS; BONE NEOPLASMS; CELL LINE, TUMOR; CELL PROLIFERATION; CHONDROSARCOMA; DISEASE PROGRESSION; DOXORUBICIN; DRUG RESISTANCE, NEOPLASM; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; INHIBITOR OF APOPTOSIS PROTEINS; NEOPLASM STAGING; RNA, SMALL INTERFERING; TRANSGENES;

EID: 79953254209     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-11-120     Document Type: Article

References (29)

1. World Health Organization Pathology and Genetics. Tumours of Soft Tissue and Bone. World Health Organization Classification of Tumours. Cartilage tumours 2002, 234-257. Lyon, IARC Press, Fletcher CD, Unni KK, Mertens F, World Health Organization.
2. Damron TA, Ward WG, Stewart A. Osteosarcoma, chondrosarcoma, and Ewing's sarcoma: National Cancer Data Base Report. Clin Orthop Relat Res 2007, 459:40-7. 10.1097/BLO.0b013e318059b8c9, 17414166.
3. Eriksson AI, Schiller A, Mankin HJ. The management of chondrosarcoma of bone. Clin Orthop 1980, 153:44-66.
4. Dorfmann HD, Czerniak B. Bone Tumors. 1998, Mosby, St. Louis.
5. Gelderblom H, Hogendoorn PC, Dijkstra SD, van Rijswijk CS, Krol AD, Taminiau AH, Bovée JV. The clinical approach towards chondrosarcoma. Oncologist 2008, 13:320-9. 10.1634/theoncologist.2007-0237, 18378543.
6. Evans HL, Ayala AG, Romsdahl MM. Prognostic factors in chondrosarcoma of bone. A clinicopathologic analysis with emphasis on histologic grading. Cancer 1977, 40:818-31. 10.1002/1097-0142(197708)40:2<818::AID-CNCR2820400234>3.0.CO;2-B, 890662.
7. Lee FY, Mankin HJ, Fondren G, Gebhardt MC, Springfield DS, Rosenberg AE, Jennings LC. Chondrosarcoma of bone: an assessment of outcome. J Bone Joint Surg Am 1999, 81:326-38. 10.1302/0301-620X.81B5.9588, 10199270.
8. Schrage YM, Briaire-de Bruijn IH, de Miranda NF, van Oosterwijk J, Taminiau AH, van Wezel T, Hogendoorn PC, Bovée JV. Kinome Profiling of Chondrosarcoma Reveals Src-Pathway Activity and Dasatinib as Option for Treatment. Cancer Res 2009, 69:6216-6222. 10.1158/0008-5472.CAN-08-4801, 19602594.
9. Bovée JV, Cleton-Jansen AM, Taminiau AH, Hogendoorn PC. Emerging pathways in the development of chondrosarcoma of bone and implications for targeted treatment. Lancet Oncol 2005, 6:599-607.
10. Kim DW, Kim KO, Shin MJ, Ha JH, Seo SW, Yang J, Lee FY. siRNA-based targeting of antiapoptotic genes can reverse chemoresistance in P-glycoprotein expressing chondrosarcoma cells. Mol Cancer 2009, 15(8):28.
11. Altieri DC. The case for survivin as a regulator of microtubule dynamics and cell-death decisions. Curr Opin Cell Biol 2006, 18:609-615. 10.1016/j.ceb.2006.08.015, 16934447.
12. Ambrosini G, Adida C, Altieri DC. A novel anti-apoptosis gene, survivin, expressed in cancer and lymphoma. Nat Med 1997, 3:917-921. 10.1038/nm0897-917, 9256286.
13. Verdecia MA, Huang H, Dutil E, Kaiser DA, Hunter T, Noel JP. Structure of the human anti-apoptotic protein survivin reveals a dimeric arrangement. Nat Struct Biol 2000, 7:602-608. 10.1038/77929, 10876248.
14. Altieri DC. Survivin, cancer networks and pathway-directed drug discovery. Nat Rev Cancer 2008, 8:61-70. 10.1038/nrc2293, 18075512.
15. Skoufias DA, Mollinari C, Lacroix FB, Margolis RL. Human survivin is a kinetochore-associated passenger protein. J Cell Biol 2000, 151:1575-1582. 10.1083/jcb.151.7.1575, 2150675, 11134084.
16. Kobayashi K, Hatano M, Otaki M, Ogasawara T, Tokuhisa T. Expression of a murine homologue of the inhibitor of apoptosis protein is related to cell proliferation. Proc Natl Acad Sci USA 1999, 96:1457-1462. 10.1073/pnas.96.4.1457, 15484, 9990045.
17. Fukuda S, Pelus LM. Survivin, a cancer target with an emerging role in normal adult tissues. Mol Cancer Ther 2006, 5:1087-98. 10.1158/1535-7163.MCT-05-0375, 16731740.
18. Machado I, Giner F, Mayordomo E, Carda C, Navarro S, Llombart-Bosch A. Tissue microarrays analysis in chondrosarcomas: light microscopy, immunohistochemistry and xenograft study. Diagn Pathol 2008, 15:25.
19. Lechler P, Wu X, Bernhardt W, Campean V, Gastiger S, Hackenbeck T, Klanke B, Weidemann A, Warnecke C, Amann K, Engehausen D, Willam C, Eckardt KU, Rödel F, Wiesener MS. The tumor gene survivin is highly expressed in adult renal tubular cells: implications for a pathophysiological role in the kidney. Am J Pathol 2007, 171:1483-98. 10.2353/ajpath.2007.070132, 2043510, 17982126.
20. Wiesener MS, Jurgensen JS, Rosenberger C, Scholze CK, Horstrup JH, Warnecke C, Mandriota S, Bechmann I, Frei UA, Pugh CW, Ratcliffe PJ, Bachmann S, Maxwell PH, Eckardt KU. Widespread hypoxia-inducible expression of HIF-2 in distinct cell populations of different organs. FASEB J 2003, 17:271-273.
21. Rödel F, Hoffmann J, Distel L, Herrmann M, Noisternig T, Papadopoulos T, Sauer R, Rödel C. Survivin as a radioresistance factor, and prognostic and therapeutic target for radiotherapy in rectal cancer. Cancer Res 2005, 65:4881-7.
22. Ling X, Bernacki RJ, Brattain MG, Li F. Induction of survivin expression by taxol (paclitaxel) is an early event, which is independent of taxol-mediated G2/M arrest. J Biol Chem 2004, 27915196-203.
23. Knauer SK, Bier C, Habtemichael N, Stauber RH. The Survivin-Crm1 interaction is essential for chromosomal passenger complex localization and function. EMBO Rep 2006, 12:1259-65.
24. Speth PA, Linssen PC, Boezeman JB, Wessels HM, Haanen C. Cellular and plasma adriamycin concentrations in long-term infusion therapy of leukemia patients. Cancer Chemother Pharmacol 1987, 20:305-310.
25. Olie RA, Simões-Wüst AP, Baumann B, Leech SH, Fabbro D, Stahel RA, Zangemeister-Wittke U. A novel antisense oligonucleotide targeting survivin expression induces apoptosis and sensitizes lung cancer cells to chemotherapy. Cancer Res 2000, 1:2805-9.
26. Ryan BM, O'Donovan N, Duffy MJ. Survivin: a new target for anti-cancer therapy. Cancer Treat Rev 2009, 35:553-62. 10.1016/j.ctrv.2009.05.003, 19559538.
27. Taubert H, Heidenreich C, Holzhausen H, Schulz A, Bache M, Kappler M, Eckert AW, Würl P, Melcher I, Hauptmann K, Hauptmann S, Schaser K. Expression of survivin detected by immunohistochemistry in the cytoplasm and in the nucleus is associated with prognosis of leiomyosarcoma and synovial sarcoma patients. BMC Cancer 2010, 10:65. 10.1186/1471-2407-10-65, 2850337, 20181247.
28. Engels K, Knauer SK, Metzler D, Simf C, Struschka O, Bier C, Mann W, Kovács AF, Stauber RH. Dynamic intracellular survivin in oral squamous cell carcinoma: underlying molecular mechanism and potential as an early prognostic marker. J Pathol 2007, 211:532-540. 10.1002/path.2134, 17334981.
29. Li F, Yang J, Ramnath N, Javle MM, Tan D. Nuclear or cytoplasmic expression of survivin: what is the significance?. Int J Cancer 2005, 114:509-12. 10.1002/ijc.20768, 2829944, 15578717.